<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696447</url>
  </required_header>
  <id_info>
    <org_study_id>2015-09</org_study_id>
    <nct_id>NCT02696447</nct_id>
  </id_info>
  <brief_title>Radiation Impact on Thromboembolic Events</brief_title>
  <acronym>RIT</acronym>
  <official_title>Radiation Therapy and Venous Thromboembolic Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Roanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to determine the frequency and to identify main risk factors
      for venous thromboembolism of venous thromboembolic complications in a population of cancer
      patients treated with a curative intent by ionizing radiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous Thromboembolism event</measure>
    <time_frame>6 months</time_frame>
    <description>All venous thromboembolism, whether symptomatic or discovered incidentally, objectified (CT angiography, lung scintigraphy, venous Doppler) between J1 of radiation treatment, up to 6 months following discontinuation of radiation treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage of D-dimer</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of VTE</measure>
    <time_frame>6 months</time_frame>
    <description>Time of occurrence of VTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic VTE</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic VTE.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cancer treated by radiotherapy</arm_group_label>
    <description>Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biomarkers assays</intervention_name>
    <description>D-Dimer assays, C-reactive protein, blood platelets assays</description>
    <arm_group_label>Cancer treated by radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with a solid (all locations) treated with radiation therapy and / or brachytherapy
        as curative intent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a solid cancer (all locations) treated with radiation therapy and / or
             brachytherapy as curative intent

          -  to be 18

        Exclusion Criteria:

          -  Patient with metastatic cancer,

          -  Patients whose follow-up at 6 months is not possible

          -  Patient receiving an anti-coagulative medication (curative doses)

          -  Pregnant or breastfeeding women,

          -  Person under protection of justice or unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas MAGNE, MD</last_name>
    <phone>(0) 4 77 91 60 25</phone>
    <email>nicolas.magne@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent Bertoletti, MD</last_name>
    <phone>04 77 12 77 88</phone>
    <email>laurent.bertoletti@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe Sucheaud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Sucheaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD-PhD</last_name>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 7, 2016</lastchanged_date>
  <firstreceived_date>February 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiation therapy</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
